The Role of Bioprinting in HealthTech Investments

July 28, 2024

Bioprinting technology represents a frontier in healthcare innovation, promising to revolutionize medical procedures and patient care. Leveraging 3D printing technologies and biomaterials, bioprinting offers unprecedented precision and customization in creating tissues and organs. The significance of bioprinting in HealthTech cannot be overstated, as it holds the potential to address critical medical needs and drive forward the capabilities of modern medicine. This blog aims to explore the role of bioprinting in HealthTech investments, providing insights into its applications, benefits, challenges, and future prospects.


Understanding Bioprinting


Bioprinting is an advanced form of 3D printing that uses cells, growth factors, and biomaterials to fabricate biomedical parts, often with the aim of replicating natural tissue characteristics. The scope of bioprinting encompasses a wide range of medical applications, from tissue engineering to the creation of complex organ structures. Key components of bioprinting technology include:


  1. 3D Printing Technology: This forms the basis of bioprinting, allowing for the precise layering of biomaterials to create three-dimensional structures.
  2. Biomaterials: These are substances used to interact with biological systems for medical purposes. Biomaterials in bioprinting can include hydrogels, polymers, and composites that provide a scaffold for cell attachment and growth.
  3. Living Cells: Essential for creating tissues and organs that can function within the human body, living cells are carefully cultured and incorporated into bioprinted structures.


Examples of bioprinting applications in healthcare are vast. They range from printing skin grafts for burn victims to creating organoids for drug testing, and even the potential future creation of full-scale organs for transplantation.



Benefits of Bioprinting


The benefits of bioprinting are multifaceted, impacting both the precision of medical procedures and the overall efficiency of healthcare delivery. Here are some key benefits:


  1. Improved Precision and Efficiency: Bioprinting allows for highly precise fabrication of tissues and organs, tailored to the specific needs of individual patients. This precision reduces the risks associated with traditional transplants and surgeries.
  2. Personalized Medicine: By using a patient’s own cells, bioprinting can create personalized tissues and organs, significantly lowering the chances of immune rejection and improving patient outcomes.
  3. Tissue Engineering: Bioprinting facilitates the development of tissue models for research and drug testing, accelerating the development of new treatments and therapies.
  4. Cost Savings and Resource Optimization: While the initial costs of bioprinting technology can be high, the long-term savings in terms of reduced need for donor organs and decreased hospital stays can be substantial.


Case Studies of Bioprinting in Healthcare


Several case studies highlight the transformative potential of bioprinting in healthcare:


  1. Skin Grafts for Burn Victims: Bioprinting has been successfully used to create skin grafts tailored to individual burn victims. This technology not only speeds up the healing process but also reduces the risk of complications and infections associated with traditional grafting techniques.
  2. Creating Organoids for Drug Testing: Researchers have used bioprinting to create organoids—miniature, simplified versions of organs—that can be used for drug testing. This innovation allows for more accurate predictions of how drugs will interact with human tissues, reducing the need for animal testing and speeding up the development of new medications.
  3. Developing Customized Implants: Bioprinting has enabled the creation of customized implants that perfectly match the patient's anatomy. This has been particularly useful in dental and orthopedic applications, where precise fitting is crucial for success.


The impact of these bioprinting solutions on patient outcomes and healthcare delivery is profound, demonstrating improved healing times, reduced rejection rates, and overall better patient experiences.


Challenges and Risks


Despite its promising potential, bioprinting faces several challenges and risks:


  1. Technical Challenges: The complexity of creating functional tissues and organs that can integrate seamlessly with the human body is a significant hurdle. Issues such as vascularization (the creation of blood vessel networks within printed tissues) remain a major challenge.
  2. Regulatory and Compliance Hurdles: Bioprinting technologies must navigate a complex regulatory landscape to ensure safety and efficacy. Obtaining approval from regulatory bodies like the FDA can be a lengthy and uncertain process.
  3. Ethical Considerations: The use of human cells and the potential for creating entire organs raise ethical questions about the extent to which bioprinting should be pursued and the regulations that should govern its use.


Strategies for overcoming these challenges include continued research and development, collaborations between industry and regulatory bodies, and robust ethical frameworks to guide the application of bioprinting technologies.


Future Trends and Innovations


The future of bioprinting is bright, with several emerging trends and innovations set to further advance the field:

  1. Enhanced Biomaterials: Advances in biomaterials will enable the creation of more complex and functional tissues. Researchers are exploring new materials that can better mimic the properties of natural tissues.
  2. Integration of AI and Machine Learning: AI and machine learning are being integrated into bioprinting processes to optimize printing parameters and improve the accuracy and functionality of printed tissues.
  3. Expansion of Applications: The range of applications for bioprinting is expected to expand significantly, with potential uses in areas such as organ transplantation, regenerative medicine, and personalized drug development.

Predictions for the next decade include the development of more sophisticated bioprinted organs, increased use of bioprinting for personalized treatments, and greater integration of bioprinting technologies into mainstream healthcare practices.


Investment Opportunities in Bioprinting


Investing in bioprinting presents a unique opportunity to be part of a rapidly evolving and impactful sector of HealthTech. Key areas for investment include:

  1. Promising Companies and Technologies: Identifying innovative companies that are leading the way in bioprinting technology. This includes startups and established companies that are developing cutting-edge bioprinting solutions.
  2. Factors to Consider: When investing in bioprinting, it is important to consider the technological viability, regulatory pathway, market potential, and the expertise of the company's leadership team.
  3. Long-Term vs. Short-Term Strategies: While bioprinting offers significant long-term potential, investors should also consider short-term strategies to capitalize on emerging trends and technologies. Diversifying investments across different aspects of bioprinting, such as materials, equipment, and applications, can also mitigate risks.


Bioprinting stands at the intersection of innovation and healthcare, offering transformative potential for medical procedures and patient care. By investing in bioprinting technologies, stakeholders can not only contribute to the advancement of healthcare but also capitalize on a high-growth, impactful sector of the HealthTech industry.


As the technology continues to evolve, the integration of bioprinting into healthcare practices is expected to become more widespread, leading to improved patient outcomes, cost savings, and enhanced capabilities in personalized medicine. Stakeholders are encouraged to support and invest in bioprinting solutions, driving forward the future of healthcare and making a tangible difference in patient lives.


Bioprinting technology represents a frontier in healthcare innovation, promising to revolutionize medical procedures and patient care. Leveraging 3D printing technologies and biomaterials, bioprinting offers unprecedented precision and customization in creating tissues and organs. The significance of bioprinting in HealthTech cannot be overstated, as it holds the potential to address critical medical needs and drive forward the capabilities of modern medicine. This blog aims to explore the role of bioprinting in HealthTech investments, providing insights into its applications, benefits, challenges, and future prospects.


Understanding Bioprinting


Bioprinting is an advanced form of 3D printing that uses cells, growth factors, and biomaterials to fabricate biomedical parts, often with the aim of replicating natural tissue characteristics. The scope of bioprinting encompasses a wide range of medical applications, from tissue engineering to the creation of complex organ structures. Key components of bioprinting technology include:


3D Printing Technology

This forms the basis of bioprinting, allowing for the precise layering of biomaterials to create three-dimensional structures. The technology has evolved significantly, with advancements in precision, speed, and material compatibility making bioprinting more viable and effective.


Biomaterials

These are substances used to interact with biological systems for medical purposes. Biomaterials in bioprinting can include hydrogels, polymers, and composites that provide a scaffold for cell attachment and growth. The choice of biomaterials is crucial, as they need to mimic the physical and chemical properties of natural tissues.


Living Cells

Essential for creating tissues and organs that can function within the human body, living cells are carefully cultured and incorporated into bioprinted structures. The ability to use a patient’s own cells can reduce the risk of immune rejection and improve

the success rates of bioprinted tissues and organs.


Growth Factors and Bioinks

Growth factors are biologically active molecules that influence cell growth and differentiation. In bioprinting, bioinks are used, which are combinations of cells and biomaterials. These bioinks must be carefully formulated to ensure that they provide the right environment for cell growth and function once printed into the desired shapes.


Applications of Bioprinting in Healthcare


The potential applications of bioprinting in healthcare are vast and varied. Here are some of the most promising areas where bioprinting is making an impact:


Tissue Engineering

One of the primary applications of bioprinting is in tissue engineering. This involves creating functional tissue for medical purposes, such as repairing or replacing damaged tissues. Examples include skin grafts for burn victims, cartilage for joint repairs, and even more complex tissues like liver patches that can assist in liver function while a patient awaits a transplant.


Organ Printing

The ultimate goal of bioprinting is to create fully functional organs for transplantation. While this is still largely in the experimental stage, there have been significant advancements. Researchers are working on printing kidneys, hearts, and lungs. These organs are built layer by layer, incorporating multiple cell types and structures to replicate the complexity of natural organs.


Drug Testing and Development

Bioprinting can create tissue models that closely mimic human organs, providing a more accurate platform for drug testing. This can reduce the reliance on animal models, which often do not predict human responses accurately, and streamline the development process for new drugs.


Personalized Medicine

Bioprinting can create customized medical solutions tailored to individual patients. This includes personalized implants and prosthetics that match the exact anatomical features of the patient, enhancing comfort and functionality.


Benefits of Bioprinting


The benefits of bioprinting are multifaceted, impacting both the precision of medical procedures and the overall efficiency of healthcare delivery. Here are some key benefits:


Improved Precision and Efficiency

Bioprinting allows for highly precise fabrication of tissues and organs, tailored to the specific needs of individual patients. This precision reduces the risks associated with traditional transplants and surgeries.


Personalized Medicine

By using a patient’s own cells, bioprinting can create personalized tissues and organs, significantly lowering the chances of immune rejection and improving patient outcomes. This personalized approach ensures that the medical treatments are better suited to the patient’s unique biological makeup.


Tissue Engineering

Bioprinting facilitates the development of tissue models for research and drug testing, accelerating the development of new treatments and therapies. This has implications for the speed and safety of bringing new drugs to market.


Cost Savings and Resource Optimization

While the initial costs of bioprinting technology can be high, the long-term savings in terms of reduced need for donor organs, decreased hospital stays, and improved treatment outcomes can be substantial. This economic efficiency is attractive to healthcare providers and patients alike.


Notable Labs’ Focus on Bioprinting in HealthTech Investments


Notable Labs is pioneering advances in HealthTech through its cutting-edge precision medicine platform. While their primary focus isn't bioprinting, their approach to personalized treatment leverages advanced genetic and molecular analyses, demonstrating the potential of integrating bioprinting technologies in the future. By tailoring healthcare solutions to individual patient profiles, Notable Labs exemplifies the transformative impact of innovative technologies in healthcare. Their work sets a benchmark for the integration of next-generation HealthTech solutions, including bioprinting, in personalized medicine. For more information, visit Notable Labs.


Case Studies of Bioprinting in Healthcare


Several case studies highlight the transformative potential of bioprinting in healthcare:


Skin Grafts for Burn Victims

Bioprinting has been successfully used to create skin grafts tailored to individual burn victims. This technology not only speeds up the healing process but also reduces the risk of complications and infections associated with traditional grafting techniques. For instance, researchers have developed bioprinted skin grafts that incorporate the patient’s own cells, promoting better integration and healing.


Creating Organoids for Drug Testing

Researchers have used bioprinting to create organoids—miniature, simplified versions of organs—that can be used for drug testing. This innovation allows for more accurate predictions of how drugs will interact with human tissues, reducing the need for animal testing and speeding up the development of new medications. For example, bioprinted liver organoids have been used to test the hepatotoxicity of new drugs, providing early insights into potential adverse effects.


Developing Customized Implants

Bioprinting has enabled the creation of customized implants that perfectly match the patient's anatomy. This has been particularly useful in dental and orthopedic applications, where precise fitting is crucial for success. Custom bioprinted bone grafts, for instance, have shown promise in repairing complex fractures and defects.


Challenges and Risks


Despite its promising potential, bioprinting faces several challenges and risks:


Technical Challenges

The complexity of creating functional tissues and organs that can integrate seamlessly with the human body is a significant hurdle. Issues such as vascularization (the creation of blood vessel networks within printed tissues) remain a major challenge. Ensuring that bioprinted tissues receive sufficient nutrients and oxygen is critical for their survival and functionality.


Regulatory and Compliance Hurdles

Bioprinting technologies must navigate a complex regulatory landscape to ensure safety and efficacy. Obtaining approval from regulatory bodies like the FDA can be a lengthy and uncertain process. Regulations must balance innovation with patient safety, which can slow down the approval and commercialization of new bioprinting applications.


Ethical Considerations

The use of human cells and the potential for creating entire organs raise ethical questions about the extent to which bioprinting should be pursued and the regulations that should govern its use. Issues such as consent, the source of cells, and the implications of creating human tissues in the lab need careful consideration.


Future Trends and Innovations


The future of bioprinting is bright, with several emerging trends and innovations set to further advance the field:


Enhanced Biomaterials

Advances in biomaterials will enable the creation of more complex and functional tissues. Researchers are exploring new materials that can better mimic the properties of natural tissues. For example, smart biomaterials that respond to environmental changes (e.g., temperature, pH) are being developed to enhance the functionality of bioprinted structures.


Integration of AI and Machine Learning

AI and machine learning are being integrated into bioprinting processes to optimize printing parameters and improve the accuracy and functionality of printed tissues. Machine learning algorithms can analyze vast amounts of data to predict the best conditions for cell growth and tissue development.


Expansion of Applications

The range of applications for bioprinting is expected to expand significantly, with potential uses in areas such as organ transplantation, regenerative medicine, and personalized drug development. New research is exploring the possibility of bioprinting complex organ systems and functional units that can perform specific physiological tasks.


Investment Opportunities in Bioprinting


Investing in bioprinting presents a unique opportunity to be part of a rapidly evolving and impactful sector of HealthTech. Key areas for investment include:


Promising Companies and Technologies

Identifying innovative companies that are leading the way in bioprinting technology is crucial. This includes startups and established companies that are developing cutting-edge bioprinting solutions. Investors should look for firms with strong research capabilities, proprietary technologies, and strategic partnerships.


Factors to Consider

When investing in bioprinting, it is important to consider the technological viability, regulatory pathway, market potential, and the expertise of the company's leadership team. Due diligence should include an assessment of the company’s intellectual property portfolio, clinical trial progress, and commercialization strategies.


Long-Term vs. Short-Term Strategies

While bioprinting offers significant long-term potential, investors should also consider short-term strategies to capitalize on emerging trends and technologies. Diversifying investments across different aspects of bioprinting, such as materials, equipment, and applications, can also mitigate risks. Balancing the portfolio with both high-risk, high-reward opportunities and more stable investments can optimize returns.


Conclusion


Bioprinting stands at the intersection of innovation and healthcare, offering transformative potential for medical procedures and patient care. By investing in bioprinting technologies, stakeholders can not only contribute to the advancement of healthcare but also capitalize on a high-growth, impactful sector of the HealthTech industry.


As the technology continues to evolve, the integration of bioprinting into healthcare practices is expected to become more widespread, leading to improved patient outcomes, cost savings, and enhanced capabilities in personalized medicine. Stakeholders are encouraged to support and invest in bioprinting solutions, driving forward the future of healthcare and making a tangible difference in patient lives.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts